Contract notice: Framework agreement with a single provider for the supply of agalsidase beta and agalsidase alfa
in various clinical packages and with home health care
Enzyme replacement therapy with agalsidase alfa
in patients with Fabry's disease: an analysis of registry data.
Washington, April 9 (ANI): Enzyme replacement therapy (ERT) with agalsidase alfa may slow deterioration of kidney function in men with Fabry disease, provided the treatment is started early, suggests a new study.
The results provide further evidence that ERT with agalsidase alfa may slow the progression of kidney disease, provided that ERT is initiated early in the disease process," said Michael L.
For the study, researchers pooled the results of three previous clinical trials of ERT with agalsidase alfa in 108 men with Fabry disease-a rare genetic disorder.
5 mg" (nonproprietary name: Agalsidase Alfa (Genetic
5 mg Nonproprietary Name: Agalsidase alfa (Genetic Recombination) Dose Form and Strength: Vial preparation, with 3.
03 Contract Award Notice - Successful Supplier(s): Supply of Agalsidase Alfa
(Replagal) solution for infusion 3.
Framework Agreement contract dossier dle centralized supply of drugs Cytarabine (DOE), Docetaxel (DOE), Adefovir (DOE), Liposomal Amphotericin B, velaglucerase (DOE), Anti Inhibitor Coagulant Complex, agalsidase alfa
(DOE), cabazitaxel (DOE ), Abiraterone (DOE), Parental Levetirazepam (DOE), Cetuximab (DOE), Tenofovier (DOE), Clofarabine (DOE), alglucosidase alfa (DOE), Rasburicase (DOE) and Everolimus (DOE) for Service Organizations Osakidetza